omniture
logo
Search
NEXTURN BIO INC
Media Room

Latest News

rss

RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company

SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- RosVivo Therapeutics, Inc. (hereinafter referred ...

2022-02-22 20:52 2017
RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company

Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.

SEOUL, South Korea, May 30, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscien...

2021-05-30 22:00 3186
Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.

Nexturn Bio Inc. decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA

SEOUL, South Korea, May 7, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscienc...

2021-05-07 07:00 3578
Nexturn Bio Inc. decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA

The world's first-in-class miRNA therapeutics to cure diabetes by pancreatic beta cell regeneration

SEOUL, South Korea, May 7, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscienc...

2021-05-07 07:00 2829
The world's first-in-class miRNA therapeutics to cure diabetes by pancreatic beta cell regeneration